Proton pump inhibitory therapy: Then and now

Yale Journal of Biology and Medicine

Volumn 69, Issue 2, 1996, Pages 175-186

  Schepp, Wolfgang ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR;

ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SELECTIVITY; DRUG STABILITY; DUODENUM ULCER; GASTRINOMA; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; STOMACH PH; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

HELICOBACTER PYLORI;

EID: 0030434074     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Schwarz, K. Über magen und jejunalgeschwüre. Beitr. Klin. Chir. 67:96-128, 1910.
2. Dammann, H.G., Blum, A.L., Lux, G., Rehner, M., Riecken, E.O., Schießel, R., Wienbeck, M., Witzel, L, and Berger, J. Unterschiedliche heilungstendenz der refluxösophagitis nach omeprazol und ranitidin. Dtsch. Med. Wschr. 111:123-128, 1986.
3. Klinkenberg-Knol, E.C., Jansen, K.M.B.J., Festen, H.P.M., Meuwissen, S.G., and Lamers, C.B. Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet i:349-351, 1987.
4. Vantrappen, G., Rutgeerts, L., Schurmans, P., and Coenegrachts, J.L. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig. Dis. Sci. 33:523-529, 1988.
5. Sandmark, S., Carlsson, R., Fausa, O., and Lundell, L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand. J. Gastroenterol. 23:635, 1988.
6. Havelund, T., Laursen, L.S., Skoubo-Kristensen, E., Andersen, B.N., Pedersen, S.A., Jensen, K.B., Fenger, C., Hanberg-Sorensen, F., and Lauritsen, K. Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial. Br. Med. J. 296:89-92, 1988.
7. 2 receptor antagonists. Aliment. Pharmacol. Ther. 4:593-599, 1990.
8. Koop, H., Schepp, W., Dammann, H.G., Schneider, A., Luhmann, R., and Classen, M. Comparative trial of pantoprazole and ranitidme in the treatment of reflux oesophagitis: results of a German multicentre study. J. Clin. Gastroenterol. 20:192-195, 1995.
9. Mössner, J., Hölscher, A.H., Herz, R., and Schneider, A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: a multicentre trial. Aliment. Pharmacol. Ther. 9:321-326, 1995.
10. Berstad, A. and Hatlebakk, J.G. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Aliment. Pharmacol. Ther. 7(supp. 1):34-36, 1993.
11. Tytgat, G.N.J., Nio, C.Y., and Schotborgh, R.H. Reflux esophagitis. Scand. J. Gastroenterol. 25 (suppl 175): 1-12, 1990.
12. Tytgat, G.N.J., Bianchi-Porro, G., and Feussner, H. Long-term strategy for the treatment of gastro-oesophageal reflux disease. Gastroenterol. Int. 4:21-32, 1991.
13. Koelz, H.R., Birchler, A., Bretholz, B., Bron, B., Capitaine, Y., Delemore, G., Fehr, H.F., Fumagalli, J., Gehring, J., and Gonvers, J.J. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 91:1198-1205, 1986.
14. Hetzel, D.J., Dent, J., Reed, W.D., Narielvala, F.M., Mackinnon, M., McCarthy, J.H., Mitchell, B., Beveridge, B.R., Laurence, B.H., and Gibson, G.G.. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903-912, 1988.
15. 2 blockers, antacids, and prokinetic drugs. Analysis of randomised clinical trials. Scand. J. Gastroenterol. 24(suppl 156):25-36, 1989.
16. 2RA) or omeprazole. Gastroenterology 98:A18, 1990.
17. Lundell, L., Backman, L., Ekström, P., Enander, L.H., Falkner, S., Fausa, O., Grimelius, L., Havu, N., Lind, T., and Conrath, H. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand. J. Gastroenterol. 26:248-256, 1991.
18. 2-receptor antagonists. Gastroenterol. Int. 1 (suppl 1):A847, 1988.
19. Dent, J., Yeomans, N.D., Mackinnon, M., Reed, W., Narielvala, F.M., Hetzel, D.J., Solcia, E., and Shearman, D.J. Omeprazole vs. ranitidine for prevention of relapse in reflux esophagitis: a controlled double blind trial of their efficacy and safety. Gut 35:590-598, 1994.
20. Hallerbäck, B., Unge, P., Carling, L., Edwin, B., Glise, B., Havu, N., Lyrenas, E., and Lundberg, K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 107:1305-1311, 1994.
21. Bate, C.M., Booth, S.N., Crow, J.P., Mountford, R.A., Keeling, P.W., Hepworth-Jones, B., Taylor, M.D., and Richardson, P.D. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux esophagitis. Gut 36:492-498, 1995.
22. Klinkenberg-Knol, E.C., Festen, H.P.M., Jansen, J.B.M.J., Lamers, C.B., Nelis, R, Snel, P., Luckers, A., Dekkers, C.P., Havu, N., and Meuwissen, S.G.. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. 121:161-167, 1994.
23. Hetzel, D.J., Carlsson, R., Dent, J. et al. Relapse of esophagitis after endoscopic healing: an analysis of unfavourable prognostic factors. Scand. J. Gastroenterol. 24(suppl 166):A175, 1989.
24. Zeitoun, P., Barbier, .P, Cayphas, J.P. et al. Comparison of two dosage regimens of omeprazole - 10 mg once daily and 20 mg weekends - as prophylaxis against recurrence of reflux esophagitis. Hepatogastroenterology 36:279-280, 1989.
25. Dent, J., Mackinnon, M., Reed, W. et al. Omeprazole prevents relapse of peptic esophagitis. Abstracts of the World Congress of Gastroenterology. Sydney 1990. Abingdon, England: The Medicine Group (UK) Ltd., 1990:FP4.
26. Sontag, S., Robinson, M., Roufail, W. et al. Daily omeprazole is needed to maintain healing in erosive esophagitis: a multicenter double-blind study. Am. J. Gastroenterol. 87:A1258, 1992.
27. Vigneri, S., Termini, R., Leandro, G., Badalamenti, S., Pantalena, M., Savarino, V., DiMario, F., Battaglia, G., Mela, G.S., Pilotto, A., Plebani, M., and Davi, G. A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. 333:1106-1110, 1995.
28. Patterson, D.J., Graham, D.Y., Lacey-Smith, J. et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 85:346-350, 1983.
29. Hands, L.J., Papavramidis, S., Bishop, H., Dennison, A.R., McIntyre, R.L., and Kettlewell, M.G. The natural history of peptic oesophageal strictures treated by dilatation and antireflux therapy alone. Ann. R. Coll. Surg. Engl. 71:306-309, 1989.
30. Ferguson, R., Dronfield, M.W., and Atkinson, W. Cimetidine in treatment of reflux esophagitis with peptic stricture. Br. Med. J. 2:472-474, 1979.
31. Ching, C.K., Shaheen, M.Z., and Holmes, G.K.T. Is omeprazole more effective in the treatment of resistant reflux oesophagitis and associated peptic stricture? Gastroenterology 98:A30, 1990.
32. Smith, P.M., Kerr, G.D., and Cockel, R., Ross, B A., Bate, C.M., Brown, P., Dronfield, M.W., Green, J.R., Hislop, W.S., and Theodossi, A. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 107:1312-1318, 1994.
33. Koop, H. and Arnold, R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Dig. Dis. Sci. 36:552-557, 1991.
34. Walan, A., Bader, J.P., Classen, M., Lamers, C.B.H.W., Piper, D.W., Rutgersson, and Eriksson, S. Effect of omeprazole and ranitidine on ulcer healing and relapse rate in patients with benign gastric ulcer. N. Engl. J. Med. 320:69-75, 1989.
35. Classen, M., Damman, H.G., Domschke, W., Huttemann, W., Londong, W., Rehner, M., Scholten, T., Simon, B., Witzel, L., and Berger, J. Abheilungsraten nach Omeprazole und Ranitidin-Behandlung des Ulcus ventriculi. Dtsch. Med. Wochenschr. 110:628-633, 1985.
36. Barbara L, Saggioro A, Olsson J, Cisternino M, Franceschi M. Omeprazole 20 mg om and ranitidine 150 mg bd in the healing of benign gastric ulcers: an Italian multicentre study. Gut 28:A1341, 1987.
37. Bate, C.M., Wilkinson, S.P., Bradby, G.V.H., Bateson, M.C., Hislop, W.S., Crowe, J.P., Willoughby, C.P., Peers, E.M., and Richardson, P.D. Randomized, double-blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 30:1323-1328, 1989.
38. Hotz, K., Plein, K., Schönekäs, H., and Rose, K. Superiority of pantoprazole over ranitidine in healing of uncomplicated, benign gastric ulcer. Barcelona: II. United European Gastroenterology Week; 1993, A63.
39. Takemoto, T, Namiki, M., Goto, Y., Matsuo, Y., and Miwa, T. A study of the usefulness of lansoprazole (AG-1749) in treating gastric ulcer: a comparison with famotidine by multiclinic double-blind technique. Rinshosheijnbyo 21:327-345, 1991.
40. Witzel, L., Gütz, H., Hüttemann, W., and Schepp, W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment. Pharmacol. Therapeut 9:19-24, 1995.
41. Florent, C., Forestier, S., and Joubert-Collin, M. Lansoprazole versus omeprazole: efficacy and safety in acute gastric ulcer. Gastroenterology 104:A80, 1993.
42. Classen, M., Dammann, H.G., Domschke, W., Hengels, K.J., Hüttemann, W., Londong, W., Rehner, M., Simon, B., Witzei, L., and Berger, J. Kurzzeit-Therapie des Ulcus duodeni mit Omeprazol und Ranitidin. Ergebnisse einer deutschen Multicenter Studie. Dtsch. Med. WSchr. 110:210-215, 1985.
43. Lind, T., Haglund, U., Hernqvist, H., and a Swedish Multicenter Study Group. Omeprazole or ranitidine for two or four weeks in duodenal ulcer patients: effect on healing, symptoms and ulcer recurrence during intermittent short-term treatment. Gut 30:A1488, 1989.
44. Valenzuela, J.E., Berlin, R.G., Snape, W.J., Johnson, T.L., Horshowitz, B.I., Colon-Pagan, J. et al. U.S. experience with omeprazole in duodenal ulcer: multicenter double-blind comparative study with ranitidine. Dig. Dis. Sci. 36:761-768, 1991.
45. Mulder, C.J.J., Tytgat, G.N.J., Cluysenaer, O.J.J., Nicolay, J.J., Meyer, W.W., Hazenberg, B.P. et al. Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. Aliment. Pharmacol. Ther. 3:445-451, 1989.
46. Hui, W.M., Lam, S.K., and Lau, W.Y. Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. J Gastroenterol. Hepatol. 4(suppl 2):35-43, 1989.
47. Delchier, J.C., Isal, J.P., Eriksson, S., Soule, J.C. Double-blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant ulcers. Gut 30:1173-1178, 1989.
48. Barbara, L., Blasi, A., Cheli, R., Corinaldesi, R., Dobrilla, G., Francavilla, A., Rinetti, M., Vezzaldini, P., Abbiati, R., and Gradnick, R. Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicentre study. Hepatogastroenterology 34:229-232, 1987.
49. Bardhan, K.D., Bianchi-Porro, G., Bose, K., Daly, M., Hinchliffe, R.F.C., Jonsson, E., Daly, M., Hinchliffe, R.F., Jonsson, E., Lazzaroni, M., Naesdal, J., Rikner, L., and Walan, A. A comparison of two different doses of omeprazole vs. ranitidine in treatment of duodenal ulcers. J. Clin. Gastroenterol. 8:408-413, 1986.
50. Glise, H., Martinson, J., Solhaug, J.H., Carling, L., Unge, P., Engström, G., and Hallerback, B. Two and four weeks' treatment for duodenal ulcer: symptom relief and clinical remission comparing omeprazole and ranitidine. Scand. J. Gastroenterol. 26:137-145, 1991.
51. Lanza, F., Simon, T.J., Berlin, R.G., Berman, R., Keyser, R., McCullough, A. et al. Is 20 mg the appropriate daily dosage of omeprazole for healing active duodenal ulcer in the U.S. population? Gastroenterology 100:A107, 1991.
52. McFarland, R.J., Bateson, M.C., Green, J.R.B., O'Donoughue, D.P., Dronfield, M.W., Keeling, P.W.N., Burke, G.J., Dickinson, R.J., Shreeve, D.R., and Peers, E.M. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 98:278-283, 1990.
53. Chelvam, P., Goh, K.L., Leong, Y.P., Leela, M.P., Yin, T.P., Ahmad, H., Jalleh, R., Wong, N.W., Lee, H.B., and Mahendran, T. Omeprazole compared with ranitidine once daily in the treatment of duodenal ulcer. J. Gastroenterol. Hepatol. 4(suppl 2):53-63, 1989.
54. Wang, C.Y., Wang, T.H., Lai, K.H., Siauw, C.R, Chen, P.C., Yang, K.C., Tsai, Y.T., and Sung, J.L. Double-blind comparison of omeprazole 20 mg o.m. and ranitidine 300 mg at night in duodenal ulcer: a Taiwan multicentre study. J. Gastroenterol. Hepatol. 7:572-576, 1992.
55. Gloria, V.I., Domingo, E.O., Makalinao, A.U., Zan, F.M., Rasco, E.T., Sy, C.T. A comparison of omeprazole and ranitidine in the management of patients with duodenal ulcer. Eur. J. Gastroenterol. Hepatol. 3:215-221, 1991.
56. Vilardell, F, Malagelada, J.R., Diaz-Rubio, M., Pajares, J.M., Sainz-Samitier, R., Rodrigo, J.M. et al. Omeprazole (20 mg o.m.) vs. ranitidine (300 mg at night) in the treatment of duodenal ulcer. World Congress of Gastroenterology, Sydney; 1990. Abstract 658.
57. Lysy, J., Karmeli, F, Wengrower, D., and Rachmilewitz, D. Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet activating factor, pepsinogen A, and gastrin in duodenal ulcer. Scand. J. Gastroenterol. 27:13-19, 1992.
58. Bigard, M.A., Isal, J.P., Galmiche, J.P., Ebrard, F., and Bader, J.P. Efficacité comparée de I'oméprazole et de la cimetidine dans le traitement de l'ulcére duodenal en poussée evolutive. Essai therapeutique, control multicentre francais. Gastroenterol. Clin. Biol. 11:753-757, 1987.
59. Devis, G. and the Belgian Multicenter Group. A controlled, double-blind comparison between omeprazole and cimetidine in duodenal ulcer patients - a Belgian multicenter trial. Joint Meeting of Gastroenterology. Brussels; 1987. Abstract AVII.
60. Archambault, A.P., Pare, P., Bailey, R.J., Navert, H., Williams, C.J., Freeman, H.J., Baker, S.J., Marcon, N.E., Hunt, R.H., and Sutherland, L. Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology 94:1130-1134, 1988.
61. Wilairatana, S., Kurathong, S., Atthapaisalsarudee, C., Saowaros, V., and Leethochavalit, M. Omeprazole or cimetidine once daily for the treatment of duodenal ulcers. J. Gastroenterol. Hepatol. 4(suppl 2):45-52, 1989.
62. Schiller, K.F.R., Axon, A.T.R., Carr-Locke, D.L., Cockel, R., Donovan, I.A., Edmonstone, W.M, et al. Duodenal ulcer recurrence after healing with omeprazole or cimetidine treatment: a multicenter study in the UK. Gut 30:83-91, 1989.
63. Crowe, J.P., Wilkinson, S.P., Bate, C.M., Wilioughby, C.P., Peers, E.M., Richardson, P.D.I., et al. Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Aliment Pharmacol. Ther. 3:83-91, 1989.
64. Schepp, W. and Classen, M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer: a multicentre study. Scand. J. Gastroenterol. 30:511-514, 1995.
65. Londong, W., Barth, H., Dammann, H.G., Hengels, K.J., Kleinert, R., Müller, P., Rohde, H., and Simon, B. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment. Pharmacol. Ther. 5:245-254, 1991.
66. Rehner, M., Rohner, H.G., and Schepp, W. Comparison of pantoprazole vs. omeprazole in the treatment of acute duodenal ulceration - a multicenter study. Aliment. Pharmacol. Ther. 9:411-416, 1995.
67. Petite, J.P., Sallerin, V., and Lemaire, M. Comparaison du lansoprazole et de l'oméprazole dans le traitment de l'ulcère duodénal. Étude multicentrique controlée en double aveugle. Gastroentérol. Clin. Biol. 1993.
68. Bardhan, K.D., Dhande, D., Hinchliffe, R.F.C., Morris, P., Thompson, M., Carroll, N.J.H., and Daly, M.J. Omeprazole in the treatment of ultra refractory duodenal ulcer. Gastroenterology 94:A22, 1988.
69. Brunner, G. and Harke, U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment. Pharmacol. Ther. 8(suppl 1): 59-64, 1994.
70. 2 resistant erosive reflux esophagitis. Gastroenterology 98:A113, 1990.
71. Maton, P.N., Vinayek, R., Frucht, H., McArthur, K.A., Miller, L.S., Saeed, Z.A., Gardner, J.D., and Jensen, R.T. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 97:827-836, 1989.
72. Metz, D.C., Pisegna, J.R., Fishbeyn, V.A., Benya, R.V., Feigenbaum, K.M., Koviack, P.D., and Jensen, R.T. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 103:1498-1508, 1992.
73. Jensen, R.T. Prospective study of long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment. Pharmacol. Ther. 7(suppl 1):41-50, 1993.
74. Howden, C.W., Meredith, P.A., Forrest, J.A.H., and Reid, J.L. Oral pharmacokinetics of omeprazole. Eur. J. Clin. Pharmacol. 26:641-643, 1984.
75. Bergstrand, R., Grind, M., Nyberg, G., and Olofsson, B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin. Drug Invest. 9:67-71, 1995.
76. Delhotal-Landes, B., Cournot, A.T., Vermerie, N., Dellatolas, F., Benoit, M., and Flouvat, B. The effect of food and antacids on lansoprazole absorption and disposition. Eur. J. Drug. Metab. Pharmacokinet. 3:315-320, 1991.
77. Hartmann, M., Theiß, U., Bliesath, H., Wieckhorst, G., Lühmann, R., Huber, R., Wurst, W., Postius, S., and Lücker, P.W. Comparison of the 24h intragastric pH profiles following single and repeated oral intake of pantoprazole 40 mg and omeprazole 20 mg in healthy male volunteers. Gastroenterology 104(suppl 4):A95, 1993.
78. Pue, M.A., Laroche, J., Meineke, I., and de Mey, C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur. J. Clin. Pharmacol. 44:575-578, 1993.
79. +-ATPase inhibitor, on gastric pH and serum gastrin. Aliment. Pharmacol. Ther. 6:359-372, 1992.
80. Simon, B., Müller, P, Marinis, E., Lühmann, R., Huber, R., Hartmann, M., and Wurst, W. Effect of repeated oral administration of BY 1023/SK&F-96022 - a new substituted benzimidazole derivative - on pentagastrin-stimuiated acid secretion and pharmacokinetics in man. Aliment. Pharmacol. Ther. 4:373-379, 1990.
81. Andersson, T., Andrén, K., Cederberg, C., Lagerström, P.-O., Lundborg, P., and Skanberg, I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. 29:557-563, 1990.
82. Prichard, P.J., Yeomans, N.D., Mihaly, G.W., Jones, D,B., Buckle, P.J., Jones, D.B., Buckle, P.J., Smallwood, R.A., and Louis, W.J. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 88:64-69, 1985.
83. +-ATPase inhibitor pantoprazole after single intravenous administration. Int. J. Clin. Pharmacol. Ther. 32:44-50, 1994.
84. Jansen, J.B.M.J., Lundborg, P., Baak, L.C., Greve, J., Ohman, M., Stöver, C., Röhss, K., and Lamers, C.B.H.W. Effect of single and repeated intravenous doses of omeprazole on pentagastrin-stimuiated gastric acid secretion and pharmacokinetics in man. Gut 29:75-80, 1988.
85. Andersson, T., Cederberg, C., Regardh, C.G., and Skanberg, I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur. J. Clin. Pharmacol. 39:195-197, 1990.
86. Andersson, T., Cederberg, C., Heggelund, A., et al. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest. 3:45-52, 1991.
87. +-ATPase inhibitor with improved pH stability. Eur. J. Pharmacol. 218:265-271, 1992.
88. Huber, R., Kohl, B., Sachs, G., Senn-Bilfinger, J., Simon, W.A., and Sturm, E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment. Phramacol. Ther. 9:363-378, 1995.
89. Simon, W.A., Sturm, E., and Kohl, B. High pH-selectivity versus H,K-ATPase of the novel proton pump inhibitor pantoprazole. Naunyn Schmiedebergs Arch. Pharmacol. 343(suppl):A295, 1991.
90. +-ATPase based on sites of extracytoplasmic labeling by omeprazole. Biochemistry 32:2345-2355, 1993.
91. +-ATPaSe. Biochim. Biophys. Acta. 1148:223-233, 1993.
92. 450 than omeprazole and lansoprazole. Biochem. Pharmacol. 42:347-355, 1991.
93. Penston, J.G. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment. Pharmacol. Ther. 8:369-389, 1994.
94. Tytgat, G.N.J. Review article: treatments that impact favourably upon eradication of Helicobacter pylori and ulcer recurrence. Aliment. Pharmacol. Ther. 8:359-368, 1994.
95. Pommerien, W., Braun, M., Idström, J.P., Wrangstadh, M., and Londong, W. No interaction between omeprazole and amoxicillin during combination therapy in Helicobacter pylori positive healthy subjects. Gastroenterology 108:A194, 1995.
96. Londong, W., Gorgas, R., Pommerien, W., Marsch-Ziegler, Semler, P., Rost, K.L., and Idstrom, J.P. Effect of different omeprazole doses combined with amoxicillin on intragastric pH, amoxicillin bioavailability and Helicobacter pylori eradication in duodenal ulcer patients. Gastroenterology 108:A153, 1995.
97. Goddard, A.F., Jessa, M.J., Barrett, D.A., Shaw, P.N., Idström, J.-P., Wason, C., Wrangstadh, M., and Spiller, R.C. Effect of omeprazole on the distribution of antibiotics in gastric juice. Gastroenterology 108:A102, 1995.
98. McNulty, C.A.M. Bacteriological and pharmacological basis for the treatment of Campylobacter pylori infection. Gastroenterol. Clin. Biol. 13:96B-100B, 1989.
99. Darmaillac, V., Bouchard, S., Lamouliatte, H., and Mégraud, F. Macrolides and Helicobacter pylori. Determination of MICs and effect of pH. Gastroenterology 108:A78, 1995.